MD Conference Express ADA 2011 - (Page 20)

n Continued from Page 17 SELECTED UPD ATES I N ANTI PLATELET THER APY was superior to clopidogrel in reducing CV events among the subgroup of patients with diabetes (14.1% vs 16.2%) [Ferreiro JL et al. Circulation in press]. Figure 1. TRITON-TIMI 38 Trial: Diabetic Subgroup. 18 16 14 CV Death / MI / Stroke 12.2 Prasugrel HR 0.70 p<0.001 NNT=46 Clopidogrel 17.0 The world’s most influential key opinion leaders trust MD Conference Express® to deliver authoritative, balanced, and insightful reports of the conference highlights which will change practice DIABET ES THE FROM Endpoint (%) 12 10 8 6 4 2 0 0 30 60 90 TIMI Major NonCABG Bleeds Clopidogrel Prasugrel 180 Days 270 360 eview Peer-R ific Scient ns Sessio ed OFFICIA L HIGHLI GHTS 2.6 2.5 450 Breakin g New s MD Conference Express® is issued to the medical community only after passing rigorous peer-review of y Therap s Update ation 2 Type simple classific disease, 1 and of the and n a t Type complex tha ophysiology diagnosis, may s for path re nd Jus Beyo become mo about the e implication splantationetes in tran ned diab etes: Diab g diabetes hasmore is lear nd, which hav or to organ immune diabetes" , auto cial Reproduced with permission from Wolters Kluwer Health; Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel– Thrombolysis in Myocardial Infarction 38; Wiviott SD et al. Circulation 2008;118:1626-1636. ase As fou ges r dise Latent alled "spe challen Defininand type 2. have been anothe t strategy. s of so-c rs, creating ed to type 1 distinction men types yea es link manageetes are two past few subtle nt. Diabet erent e 8. the treatme uire a diff nsplant diab ed over nt. See pag t-tra re recogniz treatme also req mo and pos and dy adults e become diagnosis e ELD Stu that hav appropriat nce the SHI in The Scie ults of both Distrib ution sup ported by ALSO IN THIS ISSU E l res hts – • Fina l Highlig tment es ical Tria Trea Diabet • Clin ind Diabetes Type 2 Beh ies for el Therap • Nov Ongoing trials, such as the ASCEND (NCT00135226) and ACCEPT-D (ISRCTN48110081) trials, will help to better define the benefit of aspirin as primary prevention, specifically among patients with diabetes. In addition, researchers are continuing to explore alternate pathways of platelet inhibition to develop potent antiplatelet drugs with minimal risk of bleeding. 5. Editors finalize publication 4. Independent expert peer-review ensures accuracy and fair balance 3. Presenting faculty confirm data and/or provide post-conference updates 2. Data-driven content referenced against primary sources The editors would like to thank the many members of the American Diabetes Association 71st Scientific Sessions presenting faculty who generously gave their time to ensure the accuracy and quality of the articles in this publication. 1. Scientific committee guides topic selection MD Conference Express fills the gap between live presentation and publication in the academic literature by applying the rigorous standard of peer-review to the creation of our medical conference highlights reports. On average, more than 20 world leaders (in consultation with the scientific steering committee) test, challenge, and critique each report prior to publication. Together, they check for appropriate presentation of scientific data, remove any bias from the articles, and ensure the most important elements of the sessions are included. For more information, please visit: www.mdconferencexpress.com 20 August 2011 www.mdconferencexpress.com  http://www.mdconferencexpress.com http://www.mdconferencexpress.com http://www.mdconferencexpress.com

Table of Contents for the Digital Edition of MD Conference Express ADA 2011

MD Conference Express ADA 2011

https://www.nxtbook.com/nxtbooks/md_conference_express/ada2011
https://www.nxtbookmedia.com